|
|
 |
 |
|
|
 |
|
|
|
VaxGen AIDS Vaccine May Produce Broader Immunity Than Previously Detected VaxGen, Inc. Brisbane, Calif. - May 29, 2001 - VaxGen, Inc. (Nasdaq: VXGN) presented laboratory data last week at a scientific conference indicating that the company's HIV/AIDS vaccine induces immune responses capable of preventing infection from a broader array of HIV strains than previously detected. The finding represents new evidence that the vaccine, AIDSVAX, may be effective against HIV strains found in nature, also known as primary isolates, or "wild type" strains. The finding was made possible by a new assay developed at VaxGen that allowed company scientists to more accurately measure how well antibodies induced by the vaccine, AIDSVAX, prevented cell-to-cell transmission of the virus. Cell-to-cell transmission, in which a diseased human cell infects healthy ones, is considered one of the major routes of spreading HIV infection.
—Posted: May 30, 2001
More news headlines: This week | Last week | Search archive
|
|
|
